Evidence-based complementary oncology: Innovative approaches to optimise standard therapy strategies

Anticancer Research

Volumn 30, Issue 5, 2010, Pages 1767-1771

  Beuth, Josef ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Complementary medicine; Evidence based medicine; Quackery; Quality of life; Review

Indexed keywords

ALTERNATIVE MEDICINE; CANCER THERAPY; CONFERENCE PAPER; EVIDENCE BASED PRACTICE; NUTRITION; ONCOLOGY; PRIORITY JOURNAL; UNITED KINGDOM;

COHORT STUDIES; COMPLEMENTARY THERAPIES; EVIDENCE-BASED MEDICINE; EXERCISE; HUMANS; HYPERTHERMIA, INDUCED; MEDICAL ONCOLOGY; MISTLETOE; NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELENIUM; TRACE ELEMENTS;

EID: 77954576913     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (43)

1. Beuth J: Evidenzbasierte Komplementäronkologie. Aktuelle Studien und Ausblick. Der Onklologe 13: 534-542, 2007.
2. Beuth J and Moss RW: Complementary oncology. Adjunctive methods in treatment of cancer. Thieme, NY, 2005.
3. Unger C and Weis J: Unkonventionelle und supportive Therapiestrategien. Wissenschaftliche Verlagsgesellschaft, Stuttgart, 2006.
4. American Cancer Society: Guidelines for using complementary and alternative medicine. 2008, www.cancer.org
5. Beuth J and Schierholz JM: Evidence-based complementary oncology. Innovative strategies to optimise standard therapy strategies. In Vivo 21: 423-428, 2007. (Pubitemid 46534301)
6. Vecchi M, Torgano G and de Franchis S: Evidence of altered structural and secretory glycoconjugates in the jejunal mucosa of patients with giuten sensitive enteropathy and subtotal villus atrophy. Gut 30: 804-810, 1989. (Pubitemid 19167782)
7. Doll R and Peto R: The causes of cancer. Quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 66: 1193-1208, 1981. (Pubitemid 11063920)
8. Prasad KN and Cole WC: Cancer and nutrition. IOS Press, Amsterdam, Netherlands, 1998.
9. Zuercher G: Tumoren. In: Kluthe R (ed.): Ernaehrungsmedizin in der Praxis: Aktuelles Handbuch zur Prophylaxe und Therapie emaehrungsabhaengiger Erkrankungen. Spitta Verlag, 2001.
10. Stiefelhagen P: Ernaehrung und Krebs - Was ist gesichert? Deutsche Zeitschrift fuer Onkologie 38: 35-39, 2006.
11. Zuercher G: Krebsdiaeten. Forum DKG 4: 49-51, 2006.
12. Landessportbund NRW: Sport in der Krebsnachsorge. Landessportbund NRW, 2005.
13. Holmes MD, Chen WY, Freskanich D et al: Physical activity and survival of breast cancer diagnosis. JAMA 293: 2479-2486, 2005. (Pubitemid 40705729)
14. Meyerhardt JA, Heseltine D, Niedzwiecki D et al: The impact of physical activity on cancer recurrence and survival inpatients with stage IH colon cancer. Findings from Intergroup trial CALBG 89803. J Clin Oncol 23: 3535-3541, 2006. (Pubitemid 46630523)
15. Tschuschke V: Psychoonkologie. Schattauer Verlag, 2005.
16. Schmitz KH, Ahmed RL, Troxel A et al: Weight lifting in women with breast cancer-related lymphedema. New Eng J Med 361: 664-673, 2009.
17. Schuele K: Bewegung und Sport in der Krebsnachsorge. Forum DKG 2: 39-41, 2001.
18. Spiegel D and Classen C: Group therapy for cancer patients. Basic behavorial science. Basic Books Publ, USA, 2000.
19. Rehse B: Metaanalytische Untersuchungen zur Lebensqualitaet adjuvant psychoonkologisch betreuter Krebsbetroffener. Shaker Verlag, Aachen, 2001.
20. Muecke R, Schomburg L, Buentzel J et al: Komplementaerer Seleneinsau in der Onkologie. Der Onkologe 2: 181-185, 2010.
21. Zimmermann T, Leonhardt H, Kersting S et al; Reduction of postoperative lymphedema after oral tumor surgery with sodium selenite. Biol Trace Elem Res 106: 193-203, 2005.
22. Kasseroller RG and Schrauzer GN: Treatment of secondary lymphedema of the arm with physical decongestive therapy and sodium selenite. Am J Ther 7: 273-279, 2000.
23. Hehr T, Bamberg M, Rodemann HP: Praeklinische und klinische Relevanz der radioprotektiven Wirkung von Natriumselenit. InFo Onkol S2: 25-29, 1999.
24. Roth T and Fiebig HH: Cytotoxic profile of sodium selenite (Seienase) and sodium selenite in combination with clinically used chemotherapeutic agents in human tumor models. Info Onkol S2: 30-39, 1999.
25. Muecke R: Sodium selenite in gynaecologic radiation therapy. Results of a prospective randomised observation study. Trace Elem Electrolytes 23: 173-177, 2006.
26. Popiela T, Kulig J, Hanisch J et al: Influence of complementay treatment with oral enzymes on patients with colorectal cancers: an epidemiological retrolective cohort study. Caner Chemother Pharmacol S47: 55-63, 2001.
27. Sakalova H, Bock PR, Dedik L et al: Retrospective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma. Cancer Chemother Pharmacol S47: 38-41, 2001.
28. Beuth J, Ost B, Pakdaman A et al: Impact of complementary enzyme application on the postoperative treatment results of breast cancer patients. Results of an epidemiological multicenter cohort study. Cancer Chemother Pharmacol S47: 38-44, 2001.
29. Beuth J: Proteolytic enzyme therapy in evidence-based complementary oncology. Fact or fiction? Int Cancer Ther 7: 311-316, 2008.
30. Beuth J: Evidence-based complementary medicine in breast cancer patients. Breast Care 4: 8-12, 2009.
31. Groeber U: Mikronaehrstoffe. Wissenschaftliche Verlagsgesellschaft Stuttgart, 2006.
32. Prasad KN, Cole WC, Kumar B et al: Scientific rationale for using high dose multiple micronutrients as an adjunct to standard and experimental cancer therapies. Am J Coll Nutr 20: 450-463, 2001.
33. Biesalski HK: Antioxidative Vitamine in der Praevention. Dt. Aerzteblatt 92: 1316-1321, 1995.
34. Buessing A: Biological and pharmaceutical properties of viscum album. In: Bussing A (ed.) Mistletoe. The Genus Viscum. Harwood academic publishers, pp. 123-182, 2000.
35. Kiene GS, Berrino F, Buessing A et al: Mistletoe in cancer. A systematic review on controlled clinical trials. Europ J Med Res 8: 109-119, 2003.
36. Semiglasov VF, Stepula VV, Dudov A et al: The standardized mistletoe extract PS76A2 improves quality of life in patients with breast cancer receiving CMF chemotherapy: A randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res 24: 1293-1302, 2004. (Pubitemid 38624978)
37. Semiglasov VF, Stepula VV, Dudov A et al: Quality of life is improved in breast cancer patients by standardised mistletoe extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res 26: 1519-1529, 2006.
38. Schumacher K, Schneider B, Reich G et al: Influence of postoperative complementary treatment with lectin-standardized mistletoe extract on breast cancer patients. A controlled epidemiological multicentric retrolective cohort study. Anticancer Res 23: 5081-5087, 2003.
39. Piao BK, Wang XY, Xie GR et al: Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomised controlled clinical trial. Anticancer Res 24: 303-310, 2004.
40. Horneber MA, Bueschel G, Huber R et al: Mistletoe therapy in oncology. Cochrane Database of Systematic Review 2, 2008.
41. Gemeinsamer Bundesausschuss: Verordnung von Arzneimitteln in der vertragsärztlichen Verordnung (Arzneimittel Richtlinie; AMR) Bundesanzeiger 155: 11, 2004.
42. Wust P and Hildebrand D: ESHO. 23 Congress of the European Society of Hyperthermia in Oncology. Forum DKG 4: 49-51, 2006.
43. Muenstedt K: Ratgeber unkonventionelle Krebstherapien. ecomed Verlag, Landsberg, 2005.